Dapagliflozin in Patients with Heart Failure and Reduced Ejection Fraction
Authors:
Top Cited Papers
- 21 November 2019
- journal article
- research article
- Published by Massachusetts Medical Society in New England Journal of Medicine
- Vol. 381 (21) , 1995-2008
Abstract
In patients with type 2 diabetes, inhibitors of sodium–glucose cotransporter 2 (SGLT2) reduce the risk of a first hospitalization for heart failure, possibly through glucose-independent mechanisms. More data are needed regarding the effects of SGLT2 inhibitors in patients with established heart failure and a reduced ejection fraction, regardless of the presence or absence of type 2 diabetes.Keywords
Funding Information
- AstraZeneca plc
This publication has 20 references indexed in Scilit:
- Sodium Glucose Cotransporter-2 Inhibition in Heart FailureCirculation, 2017
- Effects of Sodium-Glucose Cotransporter 2 Inhibitors for the Treatment of Patients With Heart FailureJAMA Cardiology, 2017
- Canagliflozin and Cardiovascular and Renal Events in Type 2 DiabetesNew England Journal of Medicine, 2017
- Empagliflozin and Progression of Kidney Disease in Type 2 DiabetesNew England Journal of Medicine, 2016
- A win ratio approach to comparing continuous non‐normal outcomes in clinical trialsPharmaceutical Statistics, 2016
- Empagliflozin, Cardiovascular Outcomes, and Mortality in Type 2 DiabetesNew England Journal of Medicine, 2015
- Neprilysin Inhibition to Treat Heart Failure: A Tale of Science, Serendipity, and Second ChancesEuropean Journal of Heart Failure, 2015
- Angiotensin–Neprilysin Inhibition versus Enalapril in Heart FailureNew England Journal of Medicine, 2014
- Semiparametric Regression for the Mean and Rate Functions of Recurrent EventsJournal of the Royal Statistical Society Series B: Statistical Methodology, 2000
- Development and evaluation of the Kansas City Cardiomyopathy Questionnaire: a new health status measure for heart failureJACC, 2000